文献速递慢性肾脏病

肌生成抑制素与慢性肾脏病中的肌肉萎缩

Myostatin and muscle atrophy during chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

本文综述肌生成抑制素(Mstn/GDF-8)通路在慢性肾脏病(CKD)肌肉萎缩中的作用。CKD及透析患者Mstn浓度多高于健康人,尿毒症状态下低体力活动、炎症、氧化应激、尿毒症毒素、血管紧张素II、代谢性酸中毒及糖皮质激素可增加其生成;药理抑制Mstn通路是 promising 治疗方向,但尚无研究证实CKD患者获益。

要点

  • CKD与透析患者Mstn浓度多高于健康人,与肌肉量、肌力及体能相关。
  • 低体力活动、炎症、氧化应激、尿毒症毒素、血管紧张素II、代谢性酸中毒及糖皮质激素可升高Mstn。
  • 药理抑制Mstn通路是改善横纹肌功能障碍的潜在方向,但尚无CKD获益证据。

核心结论

  • Mstn通路激活与CKD肌肉功能障碍相互关联,药理抑制该通路是 promising 的治疗方向,但迄今尚无研究证实CKD患者获益。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 多数研究报道CKD与透析患者Mstn浓度高于健康受试者。
  • Mstn抑制卫星肌细胞增殖分化,并通过激活泛素-蛋白酶体系统诱导肌细胞蛋白水解表型。
  • 血液透析或腹膜透析对Mstn清除似乎很少,可能因其在血浆中与前结构域结合后分子较大。
  • 透析患者中Mstn曾被提议作为肌肉量、肌力或体能的生物标志物,但该领域仍需更多研究。

关键数值与推荐

  • 原文未报告具体数值、阈值或推荐条款。

临床怎么用

  • CKD患者肌肉萎缩评估可关注Mstn通路,但Mstn作为生物标志物尚需更多研究验证。
  • 药理抑制Mstn通路目前仍属研究阶段,尚无CKD获益证据,不宜常规临床使用。

局限性

  • 综述未报告检索范围;Mstn作为透析患者生物标志物及Mstn通路抑制在CKD的获益均缺乏充分研究证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) patients often exhibit a low muscle mass and strength, leading to physical impairment and an increased mortality. Two major signalling pathways control protein synthesis, the insulin-like growth factor-1/Akt (IGF-1/Akt) pathway, acting as a positive regulator, and the myostatin (Mstn) pathway, acting as a negative regulator. Mstn, also known as the growth development factor-8 (GDF-8), is a member of the transforming growth factor-β superfamily, which is secreted by mature muscle cells. Mstn inhibits satellite muscle cell proliferation and differentiation and induces a proteolytic phenotype of muscle cells by activating the ubiquitin-proteasome system. Recent advances have been made in the comprehension of the Mstn pathway disturbance and its role in muscle wasting during CKD. Most studies report higher Mstn concentrations in CKD and dialysis patients than in healthy subjects. Several factors increase Mstn production in uraemic conditions: low physical activity, chronic or acute inflammation and oxidative stress, uraemic toxins, angiotensin II, metabolic acidosis and glucocorticoids. Mstn seems to be only scarcely removed during haemodialysis or peritoneal dialysis, maybe because of its large molecule size in plasma where it is linked to its prodomain. In dialysis patients, Mstn has been proposed as a biomarker of muscle mass, muscle strength or physical performances, but more studies are needed in this field. This review outlines the interconnection between Mstn activation, muscle dysfunction and CKD. We discuss mechanisms of action and efficacy of pharmacological Mstn pathway inhibition that represents a promising treatment approach of striated muscle dysfunction. Many approaches and molecules are in development but until now, no study has proved a benefit in CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Bataille S, Chauveau P, Fouque D, et al. Myostatin and muscle atrophy during chronic kidney disease. Nephrol Dial Transplant. 2021. PMID: 32974666. doi:10.1093/ndt/gfaa129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。